Tech Company Financing Transactions
MyoPax Funding Round
MyoPax, operating out of Berlin, secured investment from IBB Ventures.
Transaction Overview
Company Name
Announced On
11/4/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
IBB Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its pharmaceutical manufacturing processes, establish necessary prerequisites for its first clinical trials, and expand its underlying therapeutic platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
c/o Bayer Co.Lab, Müllerstraße 178
Berlin, 13353
DE
Berlin, 13353
DE
Phone
Website
Email Address
Overview
MyoPax is a spin-off from the Muscle Research Unit of the Charité Universitätsmedizin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association in Berlin (Website: Muscle Research Unit). Upon its launch in 2022, MyoPax joined the BioInnovation Institute in Copenhagen. We envisage becoming the international leader in biological muscle therapy. We have more than 30 years of relevant experience in human skeletal muscle research and development. We are passionate about our mission and determined to succeed. We are empowered by strong science, state-of-the-art technology and preeminent clinical expertise.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Verena Schöwel-Wolf
Co-Founder
Simone Spuler
Browse more venture capital transactions:
Prev: 11/4/2026: Titan OS venture capital transaction
Next: 11/4/2026: Sporta venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records on this site come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs